Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Values First Advisors Inc.

Values First Advisors Inc. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 8,790 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during the period. Alnylam Pharmaceuticals makes up 1.3% of Values First Advisors Inc.’s investment portfolio, making the stock its 15th largest holding. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,417,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Souders Financial Advisors increased its holdings in shares of Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 36 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 21.9% during the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 60 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 54.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 91 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $26,000. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 1.1% in the first quarter. Daiwa Securities Group Inc. now owns 10,921 shares of the biopharmaceutical company’s stock worth $1,632,000 after acquiring an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.4 %

Shares of NASDAQ:ALNY opened at $293.69 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The business has a 50 day moving average of $274.09 and a 200-day moving average of $220.55. The stock has a market cap of $37.15 billion, a PE ratio of -109.59 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The business’s revenue was up 107.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.21) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now directly owns 136 shares in the company, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock valued at $13,595,460 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 10th. TD Cowen lifted their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Six investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $290.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.